AGC Biologics, a global company involved in clinical and commercial development and manufacturing of therapeutic proteins, announced yesterday that it has named Kasper Moller as its new chief technical officer.
Moller will report to Patricio Massera, chief executive officer.
Moller joined AGC Biologics in 2006 as a scientist at the Copenhagen facility and has held the positions of principal scientist (2007) and department manager (2008) within Process Development. Beginning in 2010, Kasper led the Upstream Process Development teams and in 2011, he led process characterisation and validation activities. In 2013 - 2014, Kasper was appointed vice president of Process Development and in 2014 – 2017, Kasper was appointed vice president of Manufacturing. He has most recently served as the site head for AGC Biologics' Copenhagen facility and his role was expanded to include oversight of the Heidelberg, Germany site as well as Global Supply Chain Management and Global IT.
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme
OncoHost receives BIG Innovation Award in Health category
MemorialCare hospitals recognised in 2026 Women's Choice Awards
Champions Oncology expands bioanalytical services with new technology and leadership
PhaseV receives three industry honours for AI in clinical development
Galapagos plans to wind down cell therapy business following strategic review
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Revelation Pharma acquires Acacia Apothecary & Wellness
Viatris receives fifth consecutive recognition on Forbes' annual list of World's Best Employers
INOVIO announces inducement grant to new employee
AbbVie's Allergan Aesthetics announces Natrelle supplier agreement with Vizient